CEL-SCI Home Page
preload preload

February 2016

CEL-SCI CEO on Fox

January 2016

CEL-SCI Shareholder Letter

Press Releases

Corporate Presentations

Press Releases

September 26, 2016
NEW STORY CEL-SCI Reports Clinical Hold on Head and Neck Cancer Study

September 6, 2016
NEW STORY CEL-SCI Announces Resignation of Its Founder for Health Reasons

September 2, 2016
NEW STORY CEL-SCI Reports Monthly Patient Enrollment in August for Its Phase 3 Head and Neck Cancer Trial

August 29, 2016
NEW STORY CEL-SCI Announces the Closing of its $5 Million Registered Direct Offering

August 23, 2016
NEW STORY CEL-SCI Announces $5 Million Registered Direct Offering

August 10, 2016
NEW STORY CEL-SCI Corporation Reports Third Quarter Fiscal Year 2016 Financial Results

August 1, 2016
NEW STORY CEL-SCI Reports Monthly Patient Enrollment in Julyfor Its Phase 3 Head and Neck Cancer Trial

July 11, 2016
NEW STORY CEL-SCI Granted European Patent for Multikine Cancer Immunotherapy in Combination with Radiation and/or Chemotherapy

July 5, 2016
NEW STORY CEL-SCI Reports Monthly Patient Enrollment in June for Its Phase 3 Head and Neck Cancer Trial

June 7, 2016
NEW STORY CEL-SCI to Present at LD Micro Invitational

June 1, 2016
NEW STORY CEL-SCI Reports Monthly Patient Enrollment in May for Its Phase 3 Head and Neck Cancer Trial

May 31, 2016
NEW STORY CEL-SCI to Present At the Fifth Annual Marcum Microcap Conference

May 24, 2016
NEW STORY CEL-SCI Announces the Closing of Its $5 Million Registered Direct Offering

May 18, 2016
NEW STORY CEL-SCI Announces $5 Million Registered Direct Offering

May 10, 2016
NEW STORY CEL-SCI Corporation Reports Second Quarter Fiscal Year 2016 Financial Results

May 2, 2016
NEW STORY CEL-SCI Reports Record Monthly Patient Enrollment in April for Its Phase 3 Head and Neck Cancer Trial

April 1, 2016
NEW STORY CEL-SCI Reports Monthly Patient Enrollment in March for Its Phase 3 Head and Neck Cancer Trial

March 1, 2016
NEW STORY CEL-SCI Reports Monthly Patient Enrollment in February for Its Phase 3 Head and Neck Cancer Trial

February 9, 2016
NEW STORY CEL-SCI Corporation Reports First Quarter Fiscal 2016 Financial Results

February 1, 2016
CEL-SCI Reports Monthly Patient Enrollment in January for Its Phase 3 Head and Neck Cancer Trial

January 8, 2016
CEL-SCI Corporation Summarizes Significant Accomplishments in 2015 and Positive Momentum For 2016

January 5, 2016
CEL-SCI Reports Record Year for Patient Enrollment With 75% Increase in Its Global Phase 3 Head and Neck Cancer Trial

December 11, 2015
CEL-SCI Reports Fiscal 2015 Financial Results and Clinical & Corporate Developments

November 17, 2015
CEL-SCI Is Granted a New European Patent on Its Phase 3 Investigational Cancer Immunotherapy Multikine

November 4, 2015
CEL-SCI's Rheumatoid Arthritis Vaccine Selected for Commercialization & Program Niche Analysis Plan by U.S. National Institutes of Health

October 28, 2015
CEL-SCI Announces Closing of Public Offering for Gross Proceeds of $11.5 Million

October 14, 2015
CEL-SCI to Receive Up to $5,000,000 in Litigation Funding to Support Its Arbitration Suit Against Former CRO

October 5, 2015
Ergomed Increases Its Co-Development Contribution Up To $12,000,000 In CEL-SCI's Phase 3 Head and Neck Cancer Trial

July 20, 2015
CEL-SCI Expands Its Phase I Study For Treatment of Anal Warts in HIV/HPV Co-Infected Patients with Addition of 2nd Site at University of California San Francisco

 

ADDITIONAL RELEASES
View All Corporate Press Releases


Phase III Clinical Trial Monthly Enrollment Chart

Number of Patients Enrolled per month since the transfer to the new CROs.

Phase III Enrollment Chart


 

THE CEL-SCI STORY